<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="hwp">eLife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">07314</article-id><article-id pub-id-type="doi">10.7554/eLife.07314</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Biochemistry and Chemical Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Cell Biology</subject></subj-group></article-categories><title-group><article-title>Pharmacological dimerization and activation of the exchange factor eIF2B antagonizes the integrated stress response</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" equal-contrib="yes" id="author-3459"><name><surname>Sidrauski</surname><given-names>Carmela</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-30186"><name><surname>Tsai</surname><given-names>Jordan C</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-5202-722X</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf6"/></contrib><contrib contrib-type="author" id="author-31951"><name><surname>Kampmann</surname><given-names>Martin</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-3819-7019</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf6"/></contrib><contrib contrib-type="author" id="author-30188"><name><surname>Hearn</surname><given-names>Brian R</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-3592"><name><surname>Vedantham</surname><given-names>Punitha</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-30189"><name><surname>Jaishankar</surname><given-names>Priyadarshini</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf6"/></contrib><contrib contrib-type="author" id="author-30190"><name><surname>Sokabe</surname><given-names>Masaaki</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="conf6"/></contrib><contrib contrib-type="author" id="author-30191"><name><surname>Mendez</surname><given-names>Aaron S</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf6"/></contrib><contrib contrib-type="author" id="author-30192"><name><surname>Newton</surname><given-names>Billy W</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="conf6"/></contrib><contrib contrib-type="author" id="author-30193"><name><surname>Tang</surname><given-names>Edward L</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="conf6"/></contrib><contrib contrib-type="author" id="author-30194"><name><surname>Verschueren</surname><given-names>Erik</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-5842-6344</contrib-id><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="conf6"/></contrib><contrib contrib-type="author" id="author-30195"><name><surname>Johnson</surname><given-names>Jeffrey R</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="conf6"/></contrib><contrib contrib-type="author" id="author-30196"><name><surname>Krogan</surname><given-names>Nevan J</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="conf6"/></contrib><contrib contrib-type="author" id="author-4143"><name><surname>Fraser</surname><given-names>Christopher S</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="conf6"/></contrib><contrib contrib-type="author" id="author-30197"><name><surname>Weissman</surname><given-names>Jonathan S</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf6"/></contrib><contrib contrib-type="author" id="author-3604"><name><surname>Renslo</surname><given-names>Adam R</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf4"/></contrib><contrib contrib-type="author" id="author-30198"><name><surname>Walter</surname><given-names>Peter</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf5"/></contrib><aff id="aff1"><label>1</label><institution content-type="dept">Department of Biochemistry and Biophysics</institution>,<institution>University of California, San Francisco</institution>,<addr-line><named-content content-type="city">San Francisco</named-content></addr-line>,<country>United States</country></aff><aff id="aff2"><label>2</label><institution>Howard Hughes Medical Institution, University of California, San Francisco</institution>,<addr-line><named-content content-type="city">San Francisco</named-content></addr-line>,<country>United States</country></aff><aff id="aff3"><label>3</label><institution content-type="dept">Department of Cellular and Molecular Pharmacology</institution>,<institution>University of California, San Francisco</institution>,<addr-line><named-content content-type="city">San Francisco</named-content></addr-line>,<country>United States</country></aff><aff id="aff4"><label>4</label><institution content-type="dept">Department of Pharmaceutical Chemistry</institution>,<institution>University of California, San Francisco</institution>,<addr-line><named-content content-type="city">San Francisco</named-content></addr-line>,<country>United States</country></aff><aff id="aff5"><label>5</label><institution content-type="dept">Small Molecule Discovery Center</institution>,<institution>University of California, San Francisco</institution>,<addr-line><named-content content-type="city">San Francisco</named-content></addr-line>,<country>United States</country></aff><aff id="aff6"><label>6</label><institution content-type="dept">Department of Molecular and Cellular Biology, College of Biological Sciences</institution>,<institution>University of California, Davis</institution>,<addr-line><named-content content-type="city">Davis</named-content></addr-line>,<country>United States</country></aff><aff id="aff7"><label>7</label><institution content-type="dept">QB3, California Institute for Quantitative Biosciences</institution>,<institution>University of California, San Francisco</institution>,<addr-line><named-content content-type="city">San Francisco</named-content></addr-line>,<country>United States</country></aff><aff id="aff8"><label>8</label><institution>Gladstone Institutes</institution>,<addr-line><named-content content-type="city">San Francisco</named-content></addr-line>,<country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-1118"><name><surname>Kelly</surname><given-names>Jeffery W</given-names></name><role>Reviewing editor</role><aff><institution>Scripps Research Institute</institution>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence:<email>carmelas@me.com</email> (CS);</corresp><corresp id="cor2"><label>*</label>For correspondence:<email>peter@walterlab.ucsf.edu</email> (PW);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>15</day><month>04</month><year>2015</year></pub-date><volume>4</volume><elocation-id>e07314</elocation-id><supplementary-material><ext-link xlink:href="elife-07314-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material><history><date date-type="received"><day>04</day><month>03</month><year>2015</year></date><date date-type="accepted"><day>13</day><month>04</month><year>2015</year></date></history><permissions><copyright-statement>© 2015, Sidrauski et al</copyright-statement><copyright-year>2015</copyright-year><copyright-holder>Sidrauski et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><abstract><p>The general translation initiation factor eIF2 is a major translational control point. Multiple signaling pathways in the integrated stress response phosphorylate eIF2 serine-51, inhibiting nucleotide exchange by eIF2B. ISRIB, a potent drug-like small molecule, renders cells insensitive to eIF2α phosphorylation and enhances cognitive function in rodents by blocking long-term depression. ISRIB was identified in a phenotypic cell-based screen, and its mechanism of action remained unknown. We now report that ISRIB is an activator of eIF2B. Our reporter-based shRNA screen revealed an eIF2B requirement for ISRIB activity. Our results define ISRIB as a symmetric molecule, show ISRIB-mediated stabilization of activated eIF2B dimers, and suggest that eIF2B4 (δ-subunit) contributes to the ISRIB binding site. We also developed new ISRIB analogs, improving its EC<sub>50</sub> to 600 pM in cell culture. By modulating eIF2B function, ISRIB promises to be an invaluable tool in proof-of-principle studies aiming to ameliorate cognitive defects resulting from neurodegenerative diseases.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000011</institution-id><institution>Howard Hughes Medical Institute (HHMI)</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Sidrauski</surname><given-names>Carmela</given-names></name><name><surname>Tsai</surname><given-names>Jordan C</given-names></name><name><surname>Kampmann</surname><given-names>Martin</given-names></name><name><surname>Mendez</surname><given-names>Aaron S</given-names></name><name><surname>Weissman</surname><given-names>Jonathan S</given-names></name><name><surname>Walter</surname><given-names>Peter</given-names></name></principal-award-recipient></award-group><funding-statement>The funder had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="con" id="conf1"><p>CS: Inventors on UC patent application PCT/US2014/029568. Title: Modulators of the eIF2a pathway.</p></fn><fn fn-type="con" id="conf2"><p>BRH: Inventors on UC patent application PCT/US2014/029568. Title: Modulators of the eIF2a pathway.</p></fn><fn fn-type="con" id="conf3"><p>PV: Inventors on UC patent application PCT/US2014/029568. Title: Modulators of the eIF2a pathway.</p></fn><fn fn-type="con" id="conf4"><p>ARR: Inventors on UC patent application PCT/US2014/029568. Title: Modulators of the eIF2a pathway.</p></fn><fn fn-type="con" id="conf5"><p>PW: Inventors on UC patent application PCT/US2014/029568. Title: Modulators of the eIF2a pathway.</p></fn><fn fn-type="conflict" id="conf6"><p>The other authors declare that no competing interests exist.</p></fn></fn-group></sec></back></article>